{
"info": {
"nct_id": "NCT02475382",
"official_title": "Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC",
"inclusion_criteria": "* Sq or Non-Sq NSCLC, Stage IIIb/IV (histologically or cytologically confirmed)\n* Relapsed after 1 prior platinum-based systemic treatment\n* Eastern Cooperative Oncology Group (ECOG) Performance Status < 2\n* CNS metastasis must be treated and returned to baseline at least 2 weeks before first dose of nivolumab and off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent\n* Prior chemotherapy, Tyrosine Kinase Inhibitor (TKI) therapy or Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose\nMust have minimum age of 18 Years",
"exclusion_criteria": "* CNS metastases (untreated and/or symptomatic)\n* Carcinomatous meningitis\n* ECOG Performance status > 3\n* Corticosteroids > 10 mg prednisolone/day (or equivalent)\n* Prior treatment with anti-PD-1, anti-PD-L-1, anti-PDL2, anti-CT137 or anti-CTLA antibody, including ipilimumab or any other drugs specifically targeting T cell costimulation or checkpoint pathways",
"miscellaneous_criteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com"
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Relapsed after 1 prior platinum-based systemic treatment",
"criterions": [
{
"exact_snippets": "Relapsed after 1 prior platinum-based systemic treatment",
"criterion": "relapse",
"requirement": {
"requirement_type": "treatment history",
"expected_value": "1 prior platinum-based systemic treatment"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Relapsed after 1 prior platinum-based systemic treatment",
"criterion": "relapse",
"requirement": {
"requirement_type": "treatment history",
"expected_value": "1 prior platinum-based systemic treatment"
}
}
]
}
},
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status < 2",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status < 2",
"criterion": "ECOG Performance Status",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status < 2",
"criterion": "ECOG Performance Status",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "* CNS metastasis must be treated and returned to baseline at least 2 weeks before first dose of nivolumab and off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent",
"criterions": [
{
"exact_snippets": "CNS metastasis must be treated",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "treatment",
"expected_value": true
}
},
{
"exact_snippets": "CNS metastasis ... returned to baseline at least 2 weeks before first dose of nivolumab",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "status",
"expected_value": "returned to baseline"
}
},
{
"exact_snippets": "CNS metastasis ... returned to baseline at least 2 weeks before first dose of nivolumab",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "time since baseline",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
},
{
"exact_snippets": "off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent",
"criterion": "steroid use",
"requirement": {
"requirement_type": "status",
"expected_value": "off steroids"
}
},
{
"exact_snippets": "off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent",
"criterion": "steroid use",
"requirement": {
"requirement_type": "dose",
"expected_value": {
"operator": "<",
"value": 10,
"unit": "mg prednisone or equivalent"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "CNS metastasis must be treated",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "treatment",
"expected_value": true
}
},
{
"exact_snippets": "CNS metastasis ... returned to baseline at least 2 weeks before first dose of nivolumab",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "status",
"expected_value": "returned to baseline"
}
},
{
"exact_snippets": "CNS metastasis ... returned to baseline at least 2 weeks before first dose of nivolumab",
"criterion": "CNS metastasis",
"requirement": {
"requirement_type": "time since baseline",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent",
"criterion": "steroid use",
"requirement": {
"requirement_type": "status",
"expected_value": "off steroids"
}
},
{
"exact_snippets": "off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent",
"criterion": "steroid use",
"requirement": {
"requirement_type": "dose",
"expected_value": {
"operator": "<",
"value": 10,
"unit": "mg prednisone or equivalent"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Prior chemotherapy, Tyrosine Kinase Inhibitor (TKI) therapy or Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose",
"criterions": [
{
"exact_snippets": "Prior chemotherapy ... must be completed at least 2 weeks before first nivolumab dose",
"criterion": "prior chemotherapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Tyrosine Kinase Inhibitor (TKI) therapy ... must be completed at least 2 weeks before first nivolumab dose",
"criterion": "Tyrosine Kinase Inhibitor (TKI) therapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose",
"criterion": "immunotherapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Prior chemotherapy ... must be completed at least 2 weeks before first nivolumab dose",
"criterion": "prior chemotherapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Tyrosine Kinase Inhibitor (TKI) therapy ... must be completed at least 2 weeks before first nivolumab dose",
"criterion": "Tyrosine Kinase Inhibitor (TKI) therapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose",
"criterion": "immunotherapy",
"requirement": {
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* CNS metastases (untreated and/or symptomatic)",
"criterions": [
{
"exact_snippets": "CNS metastases",
"criterion": "CNS metastases",
"requirement": {
"requirement_type": "treatment status",
"expected_value": "untreated"
}
},
{
"exact_snippets": "CNS metastases",
"criterion": "CNS metastases",
"requirement": {
"requirement_type": "symptom status",
"expected_value": "symptomatic"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "CNS metastases",
"criterion": "CNS metastases",
"requirement": {
"requirement_type": "treatment status",
"expected_value": "untreated"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "CNS metastases",
"criterion": "CNS metastases",
"requirement": {
"requirement_type": "symptom status",
"expected_value": "symptomatic"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Carcinomatous meningitis",
"criterions": [
{
"exact_snippets": "Carcinomatous meningitis",
"criterion": "carcinomatous meningitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Carcinomatous meningitis",
"criterion": "carcinomatous meningitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* ECOG Performance status > 3",
"criterions": [
{
"exact_snippets": "ECOG Performance status > 3",
"criterion": "ECOG Performance status",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "ECOG Performance status > 3",
"criterion": "ECOG Performance status",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "N/A"
}
}
}
}
},
{
"identified_line": {
"line": "* Corticosteroids > 10 mg prednisolone/day (or equivalent)",
"criterions": [
{
"exact_snippets": "Corticosteroids > 10 mg prednisolone/day (or equivalent)",
"criterion": "corticosteroids",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg prednisolone/day (or equivalent)"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Corticosteroids > 10 mg prednisolone/day (or equivalent)",
"criterion": "corticosteroids",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg prednisolone/day (or equivalent)"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Prior treatment with anti-PD-1, anti-PD-L-1, anti-PDL2, anti-CT137 or anti-CTLA antibody, including ipilimumab or any other drugs specifically targeting T cell costimulation or checkpoint pathways",
"criterions": [
{
"exact_snippets": "Prior treatment with anti-PD-1",
"criterion": "prior treatment with anti-PD-1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-PD-L-1",
"criterion": "prior treatment with anti-PD-L-1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-PDL2",
"criterion": "prior treatment with anti-PDL2",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-CT137",
"criterion": "prior treatment with anti-CT137",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-CTLA antibody",
"criterion": "prior treatment with anti-CTLA antibody",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... ipilimumab",
"criterion": "prior treatment with ipilimumab",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... any other drugs specifically targeting T cell costimulation or checkpoint pathways",
"criterion": "prior treatment with drugs targeting T cell costimulation or checkpoint pathways",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Prior treatment with anti-PD-1",
"criterion": "prior treatment with anti-PD-1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-PD-L-1",
"criterion": "prior treatment with anti-PD-L-1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-PDL2",
"criterion": "prior treatment with anti-PDL2",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-CT137",
"criterion": "prior treatment with anti-CT137",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... anti-CTLA antibody",
"criterion": "prior treatment with anti-CTLA antibody",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Prior treatment with ... ipilimumab",
"criterion": "prior treatment with ipilimumab",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"exact_snippets": "Prior treatment with ... any other drugs specifically targeting T cell costimulation or checkpoint pathways",
"criterion": "prior treatment with drugs targeting T cell costimulation or checkpoint pathways",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
}
],
"miscellaneous_lines": [
{
"identified_line": {
"line": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com",
"criterions": []
},
"logical_structure": {
"and_criteria": []
}
}
],
"failed_inclusion": [
{
"identified_line": {
"line": "* Sq or Non-Sq NSCLC, Stage IIIb/IV (histologically or cytologically confirmed)",
"criterions": [
{
"exact_snippets": "Sq or Non-Sq NSCLC",
"criterion": "NSCLC subtype",
"requirement": {
"requirement_type": "subtype",
"expected_value": [
"Sq",
"Non-Sq"
]
}
},
{
"exact_snippets": "Stage IIIb/IV",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"IIIb",
"IV"
]
}
},
{
"exact_snippets": "histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "Sq or Non-Sq NSCLC",
"criterion": "NSCLC subtype",
"requirement": {
"requirement_type": "subtype",
"expected_value": "Sq"
}
},
{
"exact_snippets": "Sq or Non-Sq NSCLC",
"criterion": "NSCLC subtype",
"requirement": {
"requirement_type": "subtype",
"expected_value": "Non-Sq"
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "Stage IIIb/IV",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": "IIIb"
}
},
{
"exact_snippets": "Stage IIIb/IV",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": "IV"
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": "histologically"
}
},
{
"exact_snippets": "histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": "cytologically"
}
}
]
}
]
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}